Please login to the form below
OAB
This page shows the latest OAB news and features for those working in and with pharma, biotech and healthcare.
Urovant slips on phase 3 incontinence drug data
If approved, it would become the first new prescription drug in nearly a decade for OAB, claims Urovant. ... If approved by the FDA, [vibegron] could provide an exciting next-generation treatment option for patients suffering from OAB,” he added.
Latest news
-
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... hMaxi-K has been evaluated in two phase I studies in OAB patients including a small phase Ib clinical
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB patients with benign prostatic hyperplasia, plus a third trial in patients with
-
Germany’s IQWiG denies Astellas’ incontinence drug
OAB). This review will be taken into consideration by the Federal Joint Committee (GBA), which will then recommend on whether the drug should be reimbursed on Germany's healthcare system. ... The decision is in contrast to the positive guidance from the
-
Astellas uses animated bladder in campaign
The campaign is for overactive bladder (OAB) drug Myrbetriq shows an untreated bladder character constantly interrupting a woman as she goes about her daily activities (see video above or on YouTube). ... The new campaign is aimed at women aged 45-69
-
Astellas gets first OK for prostate drug Vesomni
Urology is a core product franchise for Astellas, with its standalone Harnal (tamsulosin) product for BPH and overactive bladder (OAB) therapy Vesicare (solifenacin) bringing in sales of 67bn yen and 87bn ... The company has already added to its OAB
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new ... class of OAB treatments to emerge in over 30 years, the
-
Interview: Kay Drake and Naoki Okamura, Astellas
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
-
Show stopper exposes taboo
Nearly one in five people in the UK over 40 have an overactive bladder (OAB) and live with the urgent need to go to the toilet. ... The campaign therefore needed to encourage people to set aside embarrassment, speak up about OAB and seek help.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Astellas strengthens US and Canadian leadership team
As Sabus leaves from the US, Astellas has promoted Lynn Fenicchia Gerber (pictured left) to US vice president, primary care, where she will lead sales efforts for the OAB, anti-fungal,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
emotive project Decisions in Time wins gold for the Digital solution for congress/symposium at the 2014 PM Digital Media Awards
Other emotive projects OAB Health Economics won silver in the Craft Award – Mobile and Diabetes Voyager won bronze in the Innovation Award – Pushing Boundaries. ... To get more details about Decisions in Time, OAB Health Economics,
-
Award-winning emotive project, Decisions in Time, nominated as a finalist in yet more pharmaceutical awards
Along with emotive projects like Diabetes Voyager and OAB Health Economics and Neil Kumar being nominated for Account Manager of the Year, emotive is a finalist for a total of six
-
emotive client Adam Boucher of Novo Nordisk announced as a finalist for Digital Pioneer at the 2014 PM Digital Awards
OAB Health Economics app has been nominated in the Craft Award – Mobile category. -
-
Neil Kumar announced as a finalist for Account Manager of the Year at the PM Society Digital Media Awards 2014
Decisions in Time and the OAB Health Economics app.
-
emotive is thrilled to be a sponsor of the PM Society’s Digital Media Awards 2014
Craft Award – Mobile for OAB Health Economics.
More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- Virtual congresses: video thrilled the cardio tsar
- FDA approves Roche’s Actemra COVID-19 trial
- Virtually, the same: Is it time to rethink congress strategy?
- When Wireless Technology Meets Drug Delivery
- Effective Leadership During & After the COVID-19 Pandemic
- Live Webinar: Exploring Digital Health From a Patient Perspective
- InSite Events™ National Pharma Meeting: A Customer Story
- Merck & Co halts development of potential COVID-19 drug MK-7110
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
